Harnessing heterogeneity in type 2 diabetes mellitus
- PMID: 31831872
- PMCID: PMC8035709
- DOI: 10.1038/s41574-019-0308-1
Harnessing heterogeneity in type 2 diabetes mellitus
Abstract
Personalized, or precision, medicine in type 2 diabetes mellitus is becoming a reality with new insights into the contributions of subgroup analyses. The roadmap to future implementation must take into account individual and subgroup variability in genetic architecture, environment, clinical measures, lifestyle, cost-effectiveness and treatment burden.
Conflict of interest statement
The author declares no competing interests.
References
-
- Gale EA Is type 2 diabetes a category error? Lancet 381, 1956–1957 (2013). - PubMed
-
- Del Prato S Heterogeneity of diabetes: heralding the era of precision medicine. Lancet Diabetes Endocrinol. 7, 659–661 (2019). - PubMed
-
- Ahlqvist E et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 6, 361–369 (2018). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
